Erasca (NASDAQ:ERAS) Shares Down 10.6% – What’s Next?

Erasca, Inc. (NASDAQ:ERAS)’s stock price fell 10.6% during mid-day trading on Thursday . The company traded as low as $18.98 and last traded at $19.0050. 4,325,016 shares were traded during trading, a decline of 35% from the average daily volume of 6,631,624 shares. The stock had previously closed at $21.26.

Key Stories Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: No clear positive company-specific developments were reported in the provided articles.
• Neutral Sentiment: Multiple law firms, including Robbins Geller, Rosen, Faruqi & Faruqi, KSF, Glancy Prongay, Pomerantz, and others, issued reminders about the August 10, 2026 lead-plaintiff deadline in the existing class action. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating claims tied to alleged patent-litigation exposure and patient-safety risks, reinforcing the market’s focus on legal and regulatory uncertainty around Erasca’s pipeline. Article Title
• Negative Sentiment: The class-action allegations suggest investors may have been misled about ERAS-0015’s advantages and risk profile, which can weigh on sentiment and raise concern about potential financial liabilities. Article Title

Wall Street Analyst Weigh In

ERAS has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research note on Tuesday. Stifel Nicolaus lifted their price objective on Erasca from $20.00 to $30.00 and gave the company a “buy” rating in a report on Monday, April 27th. Wall Street Zen downgraded Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HSBC set a $20.00 target price on Erasca in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.64.

Erasca Trading Up 0.8%

The company’s 50-day moving average is $14.55 and its 200-day moving average is $13.37. The firm has a market cap of $5.96 billion, a price-to-earnings ratio of -20.61 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). Equities research analysts forecast that Erasca, Inc. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Erasca

Institutional investors have recently made changes to their positions in the stock. VR Adviser LLC lifted its stake in shares of Erasca by 10.1% in the second quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after acquiring an additional 1,640,867 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in Erasca by 4.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock worth $52,672,000 after purchasing an additional 599,078 shares during the last quarter. Vanguard Group Inc. raised its holdings in Erasca by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock worth $27,930,000 after purchasing an additional 116,235 shares during the last quarter. Vivo Capital LLC lifted its position in shares of Erasca by 31.0% in the 1st quarter. Vivo Capital LLC now owns 12,151,480 shares of the company’s stock worth $196,611,000 after purchasing an additional 2,878,052 shares during the period. Finally, Siren L.L.C. boosted its stake in shares of Erasca by 28.4% in the 1st quarter. Siren L.L.C. now owns 11,244,246 shares of the company’s stock valued at $181,932,000 after purchasing an additional 2,486,997 shares during the last quarter. Institutional investors own 67.78% of the company’s stock.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.